These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Berger F; Traverse-Glehen A; Felman P; Callet-Bauchu E; Baseggio L; Gazzo S; Thieblemont C; Ffrench M; Magaud JP; Salles G; Coiffer B Clin Lymphoma; 2005 Mar; 5(4):220-4. PubMed ID: 15794852 [TBL] [Abstract][Full Text] [Related]
4. Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. Arcaini L; Varettoni M; Boveri E; Orlandi E; Rattotti S; Zibellini S; Merli M; Lucioni M; Rizzi S; Gotti M; Morello L; Pascutto C; Paulli M Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):103-5. PubMed ID: 21454204 [TBL] [Abstract][Full Text] [Related]
5. [Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry]. Hu Y; Chen Y; Wang LH; Chen X; Fang F; Liu SQ; Wu XQ; Zhu P Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):349-56. PubMed ID: 24763004 [TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118 [TBL] [Abstract][Full Text] [Related]
9. Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis. Watkins AJ; Huang Y; Ye H; Chanudet E; Johnson N; Hamoudi R; Liu H; Dong G; Attygalle A; McPhail ED; Law ME; Isaacson PG; de Leval L; Wotherspoon A; Du MQ J Pathol; 2010 Mar; 220(4):461-74. PubMed ID: 20077527 [TBL] [Abstract][Full Text] [Related]
10. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686 [TBL] [Abstract][Full Text] [Related]
11. Origin of Waldenstrom's macroglobulinaemia. García-Sanz R; Jiménez C; Puig N; Paiva B; Gutiérrez NC; Rodríguez-Otero P; Almeida J; San Miguel J; Orfão A; González M; Pérez-Andrés M Best Pract Res Clin Haematol; 2016 Jun; 29(2):136-147. PubMed ID: 27825459 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535 [TBL] [Abstract][Full Text] [Related]
13. [The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders]. Yi S; Li Z; Wang H; Liu W; Lyu R; Yu Z; Qi J; Qiu L Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):337-41. PubMed ID: 24759024 [TBL] [Abstract][Full Text] [Related]
14. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146 [TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic features and differential diagnosis of splenic B-cell marginal zone lymphoma involving bone marrow]. Sun Q; Zhang PH; Liu EB; Liu W; Li ZQ; Yang QY; Fang LH; Sun FJ; Chen HS; Qiu LG Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):234-8. PubMed ID: 23928529 [TBL] [Abstract][Full Text] [Related]
17. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Amaador K; Vos JMI; Pals ST; Kraan W; Dobber JA; Minnema MC; Koene HR; de Bruin PC; Zwinderman AH; Kersten MJ Leuk Lymphoma; 2022 May; 63(5):1070-1079. PubMed ID: 34961399 [TBL] [Abstract][Full Text] [Related]
18. Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Varettoni M; Zibellini S; Capello D; Arcaini L; Rossi D; Pascutto C; Rattotti S; Mangiacavalli S; Pochintesta L; Gotti M; Gaidano G; Cazzola M Leuk Lymphoma; 2013 Nov; 54(11):2485-9. PubMed ID: 23442064 [TBL] [Abstract][Full Text] [Related]
19. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Camacho FI; Mollejo M; Mateo MS; Algara P; Navas C; Hernández JM; Santoja C; Solé F; Sánchez-Beato M; Piris MA Am J Surg Pathol; 2001 Oct; 25(10):1268-76. PubMed ID: 11688461 [TBL] [Abstract][Full Text] [Related]
20. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Hernández JM; García JL; Gutiérrez NC; Mollejo M; Martínez-Climent JA; Flores T; González MB; Piris MA; San Miguel JF Am J Pathol; 2001 May; 158(5):1843-50. PubMed ID: 11337382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]